2020年8月
Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia.
Bone marrow transplantation
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1038/s41409-020-01009-8
- 出版者・発行元
- NATURE PUBLISHING GROUP
Aggressive NK-cell leukemia (ANKL) has a fulminant clinical course with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. Using the Japanese transplant registry data, the outcomes of 59 ANKL patients who underwent first allo-HSCT were analyzed. Twenty-nine patients received stem cells from cord blood (CB), 18 from peripheral blood, and 12 from bone marrow. At the time of transplant 21 patients had complete response (CR), and 7 partial response (PR), but 31 without response. The 1-year and 5-year overall survival (OS) were 33.9% and 27.3%, respectively. The 1-year cumulative incidences of relapse or progression was 55.5%, and that of non-relapse mortality was 12.1%. The OS was significantly better for patients with CR or PR at the time of allo-HSCT (P = 0.046), which was equivalent to that for patients who experienced primary induction failure at the time of allo-HSCT but achieved CR afterwards (40.6% versus 32.0% at 5 years;P = 0.95). Patients receiving CB had a significantly better OS than those receiving stem cells from others (37.3% versus 16.2% at 5 years;P = 0.04). Patients achieving event-free survival at 12 months after allo-HSCT had good outcomes with 5-year OS of 85.2%.
- リンク情報
-
- DOI
- https://doi.org/10.1038/s41409-020-01009-8
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/32778688
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000559626200001&DestApp=WOS_CPL
- URL
- http://europepmc.org/abstract/med/32778688
- ID情報
-
- DOI : 10.1038/s41409-020-01009-8
- ISSN : 0268-3369
- eISSN : 1476-5365
- ORCIDのPut Code : 87976429
- PubMed ID : 32778688
- Web of Science ID : WOS:000559626200001